ArticleCureus2025
Silent Myocardial Ischemia in CKD Stage 3-5: Prevalence and Predictors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilent myocardial ischemia (SMI) is a major but often underdiagnosed cardiovascular complication in patients with chronic kidney disease (CKD), particularly in advanced stages.
objectiveThis study aims to determine the prevalence of silent myocardial ischemia and identify its clinical and biochemical predictors among patients with CKD stage 3-5.
methodsThis was a cross-sectional analytical study conducted at Allama Iqbal Medical College, Lahore, Pakistan, from January 2024 to December 2024. Data were collected using a structured questionnaire specifically designed for this study. Demographic information such as age, gender, and body mass index (BMI) was recorded for each participant.
resultsThe prevalence of silent myocardial ischemia was found to be 37.4% (n = 89) in the study population. Patients with SMI were significantly older (mean age: 61.2 ± 10.5 years) compared to those without SMI (mean age: 57.1 ± 11.3 years) (p = 0.01). Diabetes mellitus was present in 82% of patients with SMI compared to 57.3% of those without (p < 0.001). Left ventricular hypertrophy (LVH) was observed in 55% of patients with SMI versus 31.4% of patients without SMI (p = 0.002). Elevated parathyroid hormone levels (>150 pg/mL) were seen in 73% of patients with SMI compared to 61% of patients without SMI (p = 0.047). Logistic regression analysis identified age > 60 years (adjusted odds ratio (AOR): 2.1; 95% confidence interval (CI): 1.2-3.5), diabetes mellitus (AOR: 2.9; 95% CI: 1.6-5.3), left ventricular hypertrophy (AOR: 2.4; 95% CI: 1.3-4.3), and elevated parathyroid hormone (PTH) levels (AOR: 1.8; 95% CI: 1.0-3.2) as independent predictors of SMI.
conclusionSilent myocardial ischemia is common in patients with CKD stage 3-5 and is independently associated with age, diabetes mellitus, left ventricular hypertrophy, and elevated PTH levels. Routine screening for SMI in high-risk patients with CKD is warranted to enable early detection and prevention of major cardiovascular events. Future longitudinal studies are recommended to assess the long-term impact of such screening and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.